Evaluating the Compatibility of New Recombinant Protein Antigens (Trivalent NRRV) with a Mock Pentavalent Combination Vaccine Containing Whole-Cell Pertussis: Analytical and Formulation Challenges.
Haemophilus influenzae
aluminum-salt adjuvant
compatibility
diphtheria
formulation
hepatitis B
non-replicating rotavirus vaccine
pediatric combination vaccine
preservatives
stability
tetanus
whole-cell pertussis
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
03 Jun 2024
03 Jun 2024
Historique:
received:
08
04
2024
revised:
21
05
2024
accepted:
30
05
2024
medline:
27
6
2024
pubmed:
27
6
2024
entrez:
27
6
2024
Statut:
epublish
Résumé
Introducing new recombinant protein antigens to existing pediatric combination vaccines is important in improving coverage and affordability, especially in low- and middle-income countries (LMICs). This case-study highlights the analytical and formulation challenges encountered with three recombinant non-replicating rotavirus vaccine (NRRV) antigens (t-NRRV formulated with Alhydrogel
Identifiants
pubmed: 38932338
pii: vaccines12060609
doi: 10.3390/vaccines12060609
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Bill & Melinda Gates Foundation
ID : OPP1212920
Pays : United States